CARM1 in human cancer: a multifunctional epigenetic node driving tumor plasticity and therapeutic vulnerability
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026
DOI: 10.1016/j.bbcan.2026.189699 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026. Verfasst von Luyao Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518055, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Neoplasms, Epigenesis, Genetic. Die Arbeit nennt 153 Literaturangaben. Gefördert von: Science, Technology and Innovation Commission of Shenzhen Municipality, Shenzhen University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Coactivator-associated arginine methyltransferase 1 (CARM1/PRMT4) is a signal-responsive epigenetic regulator that couples oncogenic and stress signals to chromatin, transcription, RNA processing, metabolism, and genome maintenance. Its effects arise from both asymmetric arginine methylation of histone and non-histone substrates and methyltransferase-independent scaffolding activities. This review critically synthesizes the structural basis, substrate networks, methylarginine readers, and cancer-contextual functions of CARM1. We propose that its apparently opposing oncogenic and tumor-suppressive activities are determined by lineage-specific substrates, regulatory post-translational modifications, cofactor and chromatin availability, and stage- or microenvironment-dependent stress signals. We further evaluate CARM1-directed therapy using an evidence-graded framework. Catalytic inhibitors such as TP-064 and EZM2302 differ in binding mode and substrate coverage, whereas emerging degraders can remove scaffolding functions but remain constrained by delivery, E3-ligase heterogeneity, pharmacokinetics, and therapeutic-window uncertainties. Biomarker-guided synthetic-lethal and immunotherapy combinations may therefore offer the most tractable route to clinical translation. This framework positions CARM1 as a context-conditioned signal-to-chromatin translator rather than a uniformly druggable oncogene.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518055, China.
- Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518055, China; Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Shenzhen University Medical Scho…
Förderung
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Shenzhen University
- National Natural Science Foundation of China
Zitieren
APA
Zhu, L., Liang, Y., Mao, Q., & Zhang, J. (2026). CARM1 in human cancer: a multifunctional epigenetic node driving tumor plasticity and therapeutic vulnerability. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2026.189699
Vancouver
Zhu L, Liang Y, Mao Q, Zhang J. CARM1 in human cancer: a multifunctional epigenetic node driving tumor plasticity and therapeutic vulnerability. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026. doi:10.1016/j.bbcan.2026.189699
BibTeX
@article{Zhu2026,
author = {Zhu, Luyao and Liang, Yajie and Mao, Qiqi and Zhang, Jun},
title = {CARM1 in human cancer: a multifunctional epigenetic node driving tumor plasticity and therapeutic vulnerability},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
doi = {10.1016/j.bbcan.2026.189699}
}
EUVIMED